Venture Capital: Seismic Therapeutics Lands $121M For AI-Powered Immunology Drug Development

“We believe the time is right to harness advances in machine learning to discover the next generation of biologics drugs to improve the lives of patients with autoimmune diseases.” – Jo Viney, PhD, Founder, President and CEO of Seismic Therapeutic.

Seismic Therapeutic has successfully concluded a $121 million Series B financing round, led by Bessemer Venture Partners and featuring participation from new investors such as Amgen Ventures, Codon Capital, and others, alongside existing investors. This funding brings the total capital raised by the machine learning immunology company to $222 million.

The proceeds will be allocated to advancing Seismic’s two lead programs, S-1117 (pan-IgG protease sculpting enzyme) and S-4321 (PD-1 agonist:Fc gamma receptor IIb selective Dual-cell Bidirectional antibody), through Phase 1 proof-of-mechanism trials. Additionally, the funding will facilitate the expansion of Seismic’s biologics pipeline and further development of its IMPACT platform, integrating machine learning to enhance drug discovery in immunology. (Businesswire)

The company’s unique approach combines machine learning with deep drug development expertise to address unmet medical needs in autoimmune diseases. Andrew Hedin from Bessemer Venture Partners will join Seismic’s board of directors as part of the financing collaboration.

Jo Viney, Founder, President, and CEO of Seismic, said the company was pioneering a new era of immunology drug development through machine learning integration.

Seismic, headquartered in the Boston biotechnology hub, focuses on transforming immunology therapy discovery and development through innovative machine learning methodologies. The IMPACT platform, central to Seismic’s strategy, employs machine learning to parallelize various drug discovery components, enabling the accelerated design and analysis of proteins and protein modifications.

This approach aims to create novel biologics with superior properties, simultaneously optimizing for biologic function, reduced immunogenicity, and developability.

Related Story:  Rapport Therapeutics Raises $150 Million For Precision Neuromedicines

Free Industry News

Subscribe to our free newsletter for updates and news about alternatives investments.

  • This field is for validation purposes and should be left unchanged.


Latest Alternative Investment News
Artificial Intelligence: AMD Takes On Rivals In The AI Chip Sweepstakes
December 7, 2023     Artificial Intelligence, News

Chipmaker AMD (NASDAQ: AMD) has unveiled a range of innovative AI solutions spanning from data centers to personal computers. The AMD Instinct MI300 Series features data center AI accelerators, while…
Digital Assets: Robinhood Debuts Crypto Trading On Its App In The EU
December 7, 2023     Digital Assets, FinTech, News

Robinhood (NASDAQ: HOOD) has launched its Crypto app in the European Union (EU), allowing eligible customers to engage in crypto trading with the added incentive of earning Bitcoin rewards. Customers…
FinTech: Samsung Electronics Ties With Mastercard’s Wallet Express
December 7, 2023     FinTech, News

Samsung Electronics (KRX: 005930) and Mastercard (NYSE: MA) have partnered to launch the Wallet Express program, offering banks and card issuers a cost-effective way to expand digital wallet offerings. Through…
Venture Capital: Revaia, Europe’s Biggest Female-Led VC Firm, Racks Up $160M For Second Fund
December 7, 2023     ESG and Sustainability, News, Venture Capital

Revaia, Europe’s largest female-founded venture capital firm, has successfully raised €150 million ($160 million) for its second fund, Revaia Growth II. The funding was secured from sovereign wealth funds, family…